Document is current
Any future updates will be listed below
-
Authors
Bock, Tamara J. https://orcid.org/0009-0006-3744-0466
Colonne, Chanukya K. https://orcid.org/0000-0003-0171-6206
Fiorenza, Salvatore https://orcid.org/0000-0003-4432-2215
Turtle, Cameron J. https://orcid.org/0000-0002-4722-4461
- License Information
-
More Information
Article History
Accepted: 27 January 2025
First Online: 18 February 2025
Competing interests
: S.F. holds patents and receives licensing fees for patents for improving the efficacy of CAR T cell therapy. S.F. is the chair of the clinical advisory board for Arovella Therapeutics and consults ad hoc for Prescient Therapeutics. C.J.T. receives research funding from 10X Genomics, Genscript, Juno Therapeutics/BMS and Nektar Therapeutics; is a member of the Scientific Advisory Boards of Advesya, ArsenalBio, Cargo Therapeutics, Caribou Biosciences, Celgene/BMS Cell Therapy, Differentia Bio, eGlint, Myeloid Therapeutics and T-CURX; is a member of the Data and Safety Monitoring Board of Kyverna; has acted as ad hoc adviser and/or consultant (in the past 12 months) to Abbvie, Century Therapeutics, Prescient Therapeutics, Novartis, and Merck Sharp and Dohme; holds stock options in ArsenalBio, Cargo Therapeutics, Caribou Biosciences, eGlint, Eureka Therapeutics and Myeloid Therapeutics; has acted as a speaker for Novartis and Pfizer; and is listed as an inventor on patents related to lisocel and other CAR T cells. The other authors declare no competing interests.
